Sarepta Therapeutics Q4 EPS Loss Forecast at $0.71 and Revenues to Fall 38%
Sarepta Therapeutics is forecast to post a $0.71 per share loss and $408.53 million in revenues for the December quarter, down 147.3% and 38% year-over-year. Consensus EPS estimates fell 45.9% in 30 days, while a +2.11% Earnings ESP and Zacks Rank 3 indicate a beat on the February 25 report.
1. Consensus Estimates and Revisions
Sarepta Therapeutics is projected to report a quarterly EPS loss of $0.71, a 147.3% year-over-year decline, on revenues of $408.53 million, down 38% from the year-ago period. Analysts have lowered consensus EPS estimates by 45.87% over the past 30 days, reflecting adjustments to late-stage program expectations and market dynamics.
2. Earnings ESP and Analyst Rank
The Most Accurate Estimate exceeds the consensus, producing an Earnings ESP of +2.11%, which historically signals a high probability of an EPS beat when combined with a Zacks Rank #3 (Hold). This suggests analysts have grown cautiously optimistic about the December-quarter results ahead of the February 25 release.
3. Potential Stock Impact and Risks
An EPS or revenue beat could drive near-term share appreciation, particularly if management highlights positive pipeline progress or future milestones. Conversely, failure to meet the lowered estimates or any negative commentary on trial developments could trigger a pullback given elevated expectations from recent revisions.